Josh Schimmers Comp Justifiable?

Don’t mean to call him out specifically. I’m sure he’s great. This is more towards places like Cantor and Leerink (others do it too I’m sure) where they have these highly highly paid SS ER analyst (Josh Schimmer @ $8 million a year for 5 years).

Now that the biotech IPO market has dried up and many don’t see it ever reaching the heights of 2021, how is paying him $8 million a year even justifiable. You have to imagine with his team and additional expenses he’s costing the company $10 to $11 million I year. His banking counterparts have to be making $2 -$5 million each at the MD level.

Don’t see how this is sustainable at some of these small banks that live on biotech shit co’s. Someone correct me if I’m wrong. Is he really bringing in that much revenue from just his research? Additionally they hired Eric Schmidt who makes similar money.


Also to add to this - Sage Kelly back during his Jefferies days as head of HC IBD made $7 million according to various articles.

Seems very steep idk though. Curious if the business model. Seems like a lot of these places are trying to position themselves as “experts” in biotech/biopharma with highly trained scientist, but places like CVP get the massive m&a fees while the experts end up on follow on and IPO deals.


Do u know what biotech ER even is? Have u seen the raising done in Q1 2024? 5 of Schimmer’s companies can raise ~$200M each and he’ll make cantor more than his salary. I know guys at smaller shops like leerink/Cowen, and even smaller life sci capital. They all make a shit ton… 


Yea prospect, I’m a doctor who’s worked in biotech ER and IB. Now I work at a top SM biotech fund.

You don’t know how these deals work do you? Maybe find a job in the industry before you just blurt random numbers out. You have no idea how thin follow on and ipo margins are. Companies employ multiple banks on these deals to get max coverage (cantor is never lead) so divide the fees by 5/6. Then account for ECM and Coverage groups cut at each of the 5 banks.

[Comment removed by mod team]
[Comment removed by mod team]
Most Helpful

They are banking on the biotech IPO market picking back up. If they can get to 10% IPO market share in a normal issuance year he more than pays for himself. However the IPO market is still basically shut so they haven’t benefitted yet. Heard he’s on a 7x6 (7m for 6 years) making NBA money. I work in healthcare IB and this has been a topic of discussion in my group (whether Cantor can take market share purely through research, which is similar to what Evercore did, except Evercore has a real advisory arm whereas Cantor will only get looks at M&A if Sage Kelly has a relationship). They’ll look like fools if market doesn’t materialize in 2025


Sure that’s fair. Difference in the evercore model is they brought ISI (a top 5 research platform at the time). Cantor paid for some really good analyst, but they don’t have as robust of a research practice as ISI.

There are some very clear terrible analyst there. Tbf I think they are starting to creep into Jefferies level of biotech analyst. Bold strategy - hope it pays off for them.

[Comment removed by mod team]

Voluptatem rem molestiae qui molestiae consequatur in. Rerum dignissimos at qui hic veniam eveniet. Voluptas veritatis error aliquam sunt sunt. Doloribus quis et deserunt provident ut.

Aspernatur et totam id alias. Velit magni quia nostrum unde.

Sit maiores quaerat hic molestias rem. Expedita id rem repellendus animi. Quam ea illum dolores pariatur magnam. Rerum rerum ut impedit illum.

Doloremque repudiandae explicabo est aliquam debitis. Ratione sit alias qui eos quisquam. Soluta dolores impedit quia molestiae. Ut praesentium cum voluptas optio vero provident.

Career Advancement Opportunities

June 2024 Investment Banking

  • Jefferies & Company 02 99.4%
  • Perella Weinberg Partners New 98.9%
  • Lazard Freres 01 98.3%
  • Harris Williams & Co. 24 97.7%
  • Goldman Sachs 16 97.1%

Overall Employee Satisfaction

June 2024 Investment Banking

  • Harris Williams & Co. 19 99.4%
  • Lazard Freres 06 98.9%
  • JPMorgan Chase 09 98.3%
  • Morgan Stanley 05 97.7%
  • Moelis & Company 01 97.1%

Professional Growth Opportunities

June 2024 Investment Banking

  • Lazard Freres 01 99.4%
  • Jefferies & Company 02 98.9%
  • Perella Weinberg Partners 18 98.3%
  • Goldman Sachs 16 97.7%
  • Moelis & Company 05 97.1%

Total Avg Compensation

June 2024 Investment Banking

  • Director/MD (5) $648
  • Vice President (22) $375
  • Associates (94) $260
  • 3rd+ Year Analyst (14) $181
  • Intern/Summer Associate (33) $170
  • 2nd Year Analyst (69) $168
  • 1st Year Analyst (206) $159
  • Intern/Summer Analyst (151) $101
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”


redever's picture
Betsy Massar's picture
Betsy Massar
Secyh62's picture
BankonBanking's picture
GameTheory's picture
dosk17's picture
kanon's picture
CompBanker's picture
DrApeman's picture
Linda Abraham's picture
Linda Abraham
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”